头孢比肟和头孢他啶治疗中重度下呼吸道感染的临床疗效及安全性评价

Comparison of the efficacy and safety between cefepime and ceftazidme in the treatment of the moderate to severe low-respiratory tract infection

目的 :比较头孢比肟和头孢他啶治疗中、重度下呼吸道感染的临床疗效及安全性评价。方法 :中重度下呼吸道感染患者 60例 ,随机分为头孢比肟组和头孢他啶组各 30例。头孢比肟组用粉针剂 1.0g 瓶。头孢他啶用粉针剂 1.0g 瓶。剂量均为 :中度感染头孢比肟 1.0g ,2次 d ,重度感染 2 .0g ,2次 d ,疗程 7～ 10d ,个别病例延长至 14d。结果 :头孢比肟组和头孢他啶组的临床治愈率分别为 73.3%和 66.7% ,临床有效率分别为 96.7%和 86.7% ,细菌清除率分别为 92 .8%和 88.0 % ,药物不良反应发生率分别为 3.3%和 6.7%。头孢比肟作用优于头孢他啶 ,但两者的差别均无统计学意义 (P >0 .0 5 )。结论 :头孢比肟是一种治疗中重度下呼吸道感染临床疗效好、不良反应少而轻微、安全的抗生素。

AIM: To compare the efficacy and safety between cefepime and ceftazidme in the treatment of the moderate to severe low-respiratory tract infection. METHODS: Sixty patients with moderate to severe low-respiratory were enrolled in two groups. 30 patents were treated with ceftzidem and other patients were given cefepine as a control. The dosage of both drugs was 1-2 g (1 g for moderate infection, 2g for severe infection). The duration of treatment was 7-10 d for most patients in the two groups. RESULTS: The efficacy rates of cefepime and ceftazidme were 96.67% and 86.67%, respectively, whereas the bacterial efficacy rates were 92.28% and 88.0% (P> 0.05). The adverse reactions in two groups were mild and the incidence were not statistical difference between two groups (P> 0.05). CONCLUSION: Cefepime is a safe and effective agent in treatment of low-respiratory tract infection like ceftazidme.